Directed Evolution of Thermostability 30323. Vainshtein, I., Atrazhev, A., Eom, S. H., Elliott, J. F., Wishart, D. S., and Malcolm,B. A. (1996) Peptide rescue of an N-terminal truncation of the Stoffel fragment oftaq DNA polymerase. <strong>Protein</strong> Sci. 5, 1785–1792.24. Shortle, D. and Lin, B. (1985) Genetic analysis of staphylococcal nuclease: identificationof three intragenic “global” suppressors of nuclease-minus mutations.Genetics 110, 539–555.25. Petrounia, I. P. and Arnold, F. H. (2000) Designed evolution of enzymatic properties.Curr. Opin. Biotechnol. 11, 325–330.26. Krebber, A., Bornhauser, S., Burmester, J., et al. (1997) Reliable cloning of functionalantibody variable domains from hybridomas and spleen cell repertoiresemploying a reengineered phage display system. J. Immunol. Methods 201, 35–55.27. Orencia, M. C., Yoon, J. S., Ness, J. E., Stemmer, W. P., and Stevens, R. C. (2001)Predicting the emergence of antibiotic resistance by directed evolution and structuralanalysis. Nat. Struct. Biol. 8, 238–242.28. Rodrigues, M. L., Presta, L. G., Kotts, C. E., et al. (1995) Development of ahumanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion proteinfor activation of a cephalosporin doxorubicin prodrug. Cancer Res. 55, 63–70.29. Huang, W. and Palzkill, T. (1997) A natural polymorphism in beta-lactamase is aglobal suppressor. Proc. Natl. Acad. Sci. USA 94, 8801–8806.30. Shindyalov, I. N. and Bourne, P. E. (1998) <strong>Protein</strong> structure alignment by incrementalcombinatorial extension (CE) of the optimal path. <strong>Protein</strong> Eng. 11, 739–747.31. Guex, N. and Peitsch, M. C. (1997) SWISS-MODEL and the Swiss-PdbViewer: anenvironment for comparative protein modeling. Electrophoresis 18, 2714–2723.32. Huang, W., Petrosino, J., Hirsch, M., Shenkin, P. S., and Palzkill, T. (1996) Aminoacid sequence determinants of beta-lactamase structure and activity. J. Mol. Biol.258, 688–703.33. Lei, S. P., Lin, H. C., Wang, S. S., Callaway, J., and Wilcox, G. (1987) Characterizationof the Erwinia carotovora pelB gene and its product pectate lyase. J. Bacteriol. 169,4379–4383.34. Yanisch-Perron, C., Vieira, J., and Messing, J. (1985) Improved M13 phage cloningvectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors.Gene 33, 103–119.35. Olins, P. O., Devine, C. S., Rangwala, S. H., and Kavka, K. S. (1988) The T7 phagegene 10 leader RNA, a ribosome-binding site that dramatically enhances theexpression of foreign genes in Escherichia coli. Gene 73, 227–235.36. Cadwell, R. C. and Joyce, G. F. (1994) Mutagenic PCR. PCR Methods Appl.3, S136–S140.37. Jelsch, C., Mourey, L., Masson, J. M., and Samama, J. P. (1993) Crystal structure ofEscherichia coli TEM1 beta-lactamase at 1.8 A resolution. <strong>Protein</strong>s 16, 364–383.38. Ambler, R. P., Coulson, A. F., Frere, J. M., et al. (1991) A standard numberingscheme for the class A beta-lactamases. Biochem. J. 276 (Pt 1), 269, 270.39. Sideraki, V., Huang, W., Palzkill, T., and Gilbert, H. F. (2001) A secondary drugresistance mutation of TEM-1 beta-lactamase that suppresses misfolding andaggregation. Proc. Natl. Acad. Sci. USA 98, 283–288.
304 Hecky et al.40. Wang, X., Minasov, G., and Shoichet, B. K. (2002) Evolution of an antibioticresistance enzyme constrained by stability and activity trade-offs. J. Mol. Biol. 320,85–95.41. Osuna, J., Perez-Blancas, A., and Soberon, X. (2002) Improving a circularly permutedTEM-1 beta-lactamase by directed evolution. <strong>Protein</strong> Eng. 15, 463–470.42. Vanhove, M., Raquet, X., and Frere, J. M. (1995) Investigation of the folding pathwayof the TEM-1 beta-lactamase. <strong>Protein</strong>s 22, 110–118.43. Zahn, R., Axmann, S. E., Rucknagel, K. P., Jaeger, E., Laminet, A. A., andPlückthun, A. (1994) Thermodynamic partitioning model for hydrophobic bindingof polypeptides by GroEL. I. GroEL recognizes the signal sequences of beta-lactamaseprecursor. J. Mol. Biol. 242, 150–164.44. Frech, C., Wunderlich, M., Glockshuber, R., and Schmid, F. X. (1996) Competitionbetween DsbA-mediated oxidation and conformational folding of RTEM1 betalactamase.Biochemistry 35, 11,386–11,395.45. Gill, S. and von Hippel, G. (1989) Calculation of protein extinction coefficientsfrom amino acid sequence data. Anal. Biochem. 182, 319–326.46. Pace, C. N. (1986) Determination and analysis of urea and guanidine hydrochloridedenaturation curves. Methods Enzymol. 131, 266–280.47. Sayle, R. A. and Milner-White, E. J. (1995) RASMOL: biomolecular graphics forall. Trends Biochem. Sci. 20, 374.48. Vriend, G. (1990) WHAT IF: a molecular modeling and drug design program. J. Mol.Graph. 8, 52–56.49. Santoro, M. M. and Bolen, D. W. (1988) Unfolding free energy changes determinedby the linear extrapolation method. 1. Unfolding of phenylmethanesulfonylalpha-chymotrypsin using different denaturants. Biochemistry 27, 8063–8068.
- Page 1 and 2:
METHODS IN MOLECULAR BIOLOGY 352Pr
- Page 4 and 5:
M E T H O D S I N M O L E C U L A R
- Page 6 and 7:
PrefaceProtein engineering is a fas
- Page 8 and 9:
ContentsPreface ...................
- Page 10 and 11:
ContributorsKATJA M. ARNDT • Inst
- Page 12:
Contributors xiKAZUNARI TAIRA • D
- Page 16 and 17:
1Combinatorial Protein Design Strat
- Page 18 and 19:
Combinatorial Protein Design Strate
- Page 20 and 21:
Combinatorial Protein Design Strate
- Page 22 and 23:
Combinatorial Protein Design Strate
- Page 24 and 25:
Combinatorial Protein Design Strate
- Page 26 and 27:
Combinatorial Protein Design Strate
- Page 28 and 29:
Combinatorial Protein Design Strate
- Page 30 and 31:
Combinatorial Protein Design Strate
- Page 32 and 33:
Combinatorial Protein Design Strate
- Page 34 and 35:
Combinatorial Protein Design Strate
- Page 36 and 37:
2Global Incorporation of Unnatural
- Page 38 and 39:
Incorporation of Unnatural Amino Ac
- Page 40 and 41:
Incorporation of Unnatural Amino Ac
- Page 42 and 43:
Incorporation of Unnatural Amino Ac
- Page 44 and 45:
Incorporation of Unnatural Amino Ac
- Page 46 and 47:
Incorporation of Unnatural Amino Ac
- Page 48 and 49:
3Considerations in the Design and O
- Page 50 and 51:
Design of Coiled Coil Structures 37
- Page 52 and 53:
Design of Coiled Coil Structures 39
- Page 54 and 55:
Design of Coiled Coil Structures 41
- Page 56 and 57:
Design of Coiled Coil Structures 43
- Page 58 and 59:
Design of Coiled Coil Structures 45
- Page 60 and 61:
Design of Coiled Coil Structures 47
- Page 62 and 63:
Design of Coiled Coil Structures 49
- Page 64 and 65:
Design of Coiled Coil Structures 51
- Page 66 and 67:
Design of Coiled Coil Structures 53
- Page 68 and 69:
Design of Coiled Coil Structures 55
- Page 70 and 71:
Design of Coiled Coil Structures 57
- Page 72 and 73:
Design of Coiled Coil Structures 59
- Page 74 and 75:
Design of Coiled Coil Structures 61
- Page 76 and 77:
Design of Coiled Coil Structures 63
- Page 78 and 79:
Design of Coiled Coil Structures 65
- Page 80 and 81:
Design of Coiled Coil Structures 67
- Page 82 and 83:
Design of Coiled Coil Structures 69
- Page 84 and 85:
4Calcium Indicators Based on Calmod
- Page 86 and 87:
Protein-Based Ca 2+ Indicators 73Fi
- Page 88 and 89:
Protein-Based Ca 2+ Indicators 7512
- Page 90 and 91:
Protein-Based Ca 2+ Indicators 77Fi
- Page 92 and 93:
Protein-Based Ca 2+ Indicators 79Fi
- Page 94 and 95:
Protein-Based Ca 2+ Indicators 8145
- Page 96 and 97:
5Design and Synthesis of Artificial
- Page 98 and 99:
Design of Zinc Finger Proteins 853.
- Page 100 and 101:
Design of Zinc Finger Proteins 873.
- Page 102 and 103:
Design of Zinc Finger Proteins 89pr
- Page 104 and 105:
Design of Zinc Finger Proteins 91Fi
- Page 106:
Design of Zinc Finger Proteins 932.
- Page 109 and 110:
96 Koide and Koidewhile retaining t
- Page 111 and 112:
98 Koide and Koide5. M9-tryptone: M
- Page 113 and 114:
100 Koide and Koidetarget-binding s
- Page 115 and 116:
102 Koide and Koide4. Discard the s
- Page 117 and 118:
104 Koide and Koideup to 1 mM for h
- Page 119 and 120:
106 Koide and Koideplate. Incubate
- Page 121 and 122:
108 Koide and Koide1. Perform steps
- Page 124 and 125:
7Engineering Site-Specific Endonucl
- Page 126 and 127:
Engineering Site-Specific Endonucle
- Page 128 and 129:
115Fig. 1. Mapping group-specific r
- Page 130 and 131:
Engineering Site-Specific Endonucle
- Page 132 and 133:
Engineering Site-Specific Endonucle
- Page 134 and 135:
Engineering Site-Specific Endonucle
- Page 136:
Engineering Site-Specific Endonucle
- Page 140 and 141:
8Protein Library Design and Screeni
- Page 142 and 143:
Protein Library Design and Screenin
- Page 144 and 145:
Protein Library Design and Screenin
- Page 146 and 147:
Protein Library Design and Screenin
- Page 148 and 149:
135Fig. 2. Excel worksheet describi
- Page 150 and 151:
137Fig. 4. Excel worksheet describi
- Page 152 and 153:
Protein Library Design and Screenin
- Page 154 and 155:
Protein Library Design and Screenin
- Page 156 and 157:
Protein Library Design and Screenin
- Page 158 and 159:
Protein Library Design and Screenin
- Page 160 and 161:
Protein Library Design and Screenin
- Page 162 and 163:
Protein Library Design and Screenin
- Page 164 and 165:
Protein Library Design and Screenin
- Page 166 and 167:
Protein Library Design and Screenin
- Page 168 and 169:
9Protein Design by Binary Patternin
- Page 170 and 171:
Protein Design by Binary Patterning
- Page 172 and 173:
Protein Design by Binary Patterning
- Page 174 and 175:
Protein Design by Binary Patterning
- Page 176 and 177:
Protein Design by Binary Patterning
- Page 178 and 179:
Protein Design by Binary Patterning
- Page 180 and 181:
10Versatile DNA Fragmentation and D
- Page 182 and 183:
NExT DNA Shuffling 169This chapter
- Page 184 and 185:
NExT DNA Shuffling 1713. Methods3.1
- Page 186 and 187:
NExT DNA Shuffling 17372°C, 4 min.
- Page 188 and 189:
NExT DNA Shuffling 175Fig. 2. Varia
- Page 190 and 191:
NExT DNA Shuffling 1773.5.1. Direct
- Page 192 and 193:
NExT DNA Shuffling 179Fig. 3. Reass
- Page 194 and 195:
181
- Page 196 and 197:
NExT DNA Shuffling 183likelihood of
- Page 198 and 199:
NExT DNA Shuffling 1853.9.2. Calibr
- Page 200 and 201:
NExT DNA Shuffling 187staining. Bec
- Page 202 and 203:
NExT DNA Shuffling 1894. Zhao, H.,
- Page 204 and 205:
11Degenerate Oligonucleotide Gene S
- Page 206 and 207:
Degenerate Oligonucleotide Gene Shu
- Page 208 and 209:
Degenerate Oligonucleotide Gene Shu
- Page 210 and 211:
Degenerate Oligonucleotide Gene Shu
- Page 212 and 213:
Degenerate Oligonucleotide Gene Shu
- Page 214 and 215:
Degenerate Oligonucleotide Gene Shu
- Page 216 and 217:
Degenerate Oligonucleotide Gene Shu
- Page 218 and 219:
12M13 Bacteriophage Coat Proteins E
- Page 220 and 221:
Engineered M13 Bacteriophage Coat P
- Page 222 and 223:
Engineered M13 Bacteriophage Coat P
- Page 224 and 225:
Engineered M13 Bacteriophage Coat P
- Page 226 and 227:
Engineered M13 Bacteriophage Coat P
- Page 228 and 229:
Engineered M13 Bacteriophage Coat P
- Page 230 and 231:
Engineered M13 Bacteriophage Coat P
- Page 232:
Engineered M13 Bacteriophage Coat P
- Page 235 and 236:
222 Fujita et al.The methods that h
- Page 237 and 238:
224 Fujita et al.3. Streptavidin an
- Page 239 and 240:
226 Fujita et al.Fig. 2. (Continued
- Page 241 and 242:
228 Fujita et al.Fig. 3. (Continued
- Page 243 and 244:
230 Fujita et al.Fig. 3. (A) Schema
- Page 245 and 246:
232 Fujita et al.1. Add 2 µg mRNA
- Page 247 and 248:
234 Fujita et al.Innovative Bioscie
- Page 249 and 250:
236 Fujita et al.30. Kim, Y., Mlsa,
- Page 251 and 252:
238 Ghadessy and Holligeraffinity m
- Page 253 and 254:
240 Ghadessy and HolligerFig. 1. (A
- Page 255 and 256:
242 Ghadessy and HolligerFinally, t
- Page 257 and 258:
244 Ghadessy and Holliger2. Prepare
- Page 259 and 260:
246 Ghadessy and Holliger2. After 6
- Page 261 and 262:
248 Ghadessy and Holliger21. Oberho
- Page 263 and 264:
250 Campbell-Valois and Michnickscr
- Page 265 and 266: 252 Campbell-Valois and Michnickfol
- Page 267 and 268: 254 Campbell-Valois and Michnick7.
- Page 269 and 270: 256 Campbell-Valois and MichnickFig
- Page 271 and 272: 258 Campbell-Valois and Michnickres
- Page 273 and 274: 260Fig. 3. BL21 pREP4 cells were co
- Page 275 and 276: 262 Campbell-Valois and MichnickFig
- Page 277 and 278: 264 Campbell-Valois and Michnickvar
- Page 279 and 280: 266 Campbell-Valois and Michnick3.
- Page 281 and 282: 268 Campbell-Valois and Michnick7.
- Page 283 and 284: 270 Campbell-Valois and Michnick21.
- Page 285 and 286: 272 Campbell-Valois and Michnick16.
- Page 287 and 288: 274 Campbell-Valois and Michnick48.
- Page 289 and 290: 276 Hecky et al.improved half-life
- Page 291 and 292: 278 Hecky et al.Fig. 1. (A) Scheme
- Page 293 and 294: 280 Hecky et al.11. Reverse primer
- Page 295 and 296: 282 Hecky et al.high variability in
- Page 297 and 298: 284 Hecky et al.coding sequence for
- Page 299 and 300: 286 Hecky et al.4. Analyze the resu
- Page 301 and 302: Table 1Amino Acid Substitutions Sel
- Page 303 and 304: 290 Hecky et al.Fig. 4. Structure o
- Page 305 and 306: 292 Hecky et al.Fig. 5. Expression
- Page 307 and 308: 294 Hecky et al.Table 2Kinetic Para
- Page 309 and 310: 296 Hecky et al.The thermoactivity
- Page 311 and 312: 298 Hecky et al.Fig. 8. Unfolding o
- Page 313 and 314: 300 Hecky et al.for the first trans
- Page 315: 302 Hecky et al.7. Thompson, M. J.
- Page 319 and 320: 306 IndexCCalcium indicators, see C
- Page 321 and 322: 308 Indexchemiocompetent cellprepar
- Page 323 and 324: 310 Indexmaterials, 169, 170mutatio
- Page 325: 312 IndexTerminal truncation, see a